Clinical Trials Logo

Filter by:
NCT ID: NCT05589779 Not yet recruiting - Asthma Clinical Trials

Relationship Between Cardiovascular Disease in Asthma and Eosinophil Subtypes and Biomarkers of Bronchial Remodeling.

Start date: April 1, 2023
Phase:
Study type: Observational

To know the clinical and inflammatory characteristics of patients with asthma and associated cardiovascular disease.

NCT ID: NCT05595902 Not yet recruiting - Healthy Clinical Trials

Normative Value for Navicular Drop Test in Older Adults

Start date: April 1, 2023
Phase:
Study type: Observational

The aim of this study is to determine the normative values of navicular height and navicular drop in individuals over 65 years of age. The secondary aim is to investigate the effects of age, gender, and body mass index on these normative values.

NCT ID: NCT05599425 Not yet recruiting - Alzheimer Disease Clinical Trials

Health Behavior Change in Midlife Adults at Risk for Alzheimer's Disease

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Modifying health behaviors like physical activity level, diet, stress, and mental activity level can lower risk for Alzheimer's disease, but many middle-aged and older adults find it difficult to sustain health behavior changes over the long term. This project will develop a new intervention that educates people about Alzheimer's disease risk factors and helps them understand how their personal health beliefs may prevent them from making long-lasting lifestyle changes. The goal is to help people sustain health behavior changes to prevent or delay the onset of Alzheimer's disease and related dementias.

NCT ID: NCT05601297 Not yet recruiting - Clinical trials for Violence Against Women

Acceptability of Women to Intimate Partner Violence and Its Correlates Among Attendants of Maternal and Child Center in Assiut

Start date: April 1, 2023
Phase:
Study type: Observational

identify acceptability of ever married women against intimate partner violence and its correlates among women attending primary health care in Assiut city.

NCT ID: NCT05604248 Not yet recruiting - Vitamin A Clinical Trials

Kinetics of Retinol and TBS Among Lactating Senegalese Women Living in an Urban Setting and the Relationship Between Their TBS and Those of Their Infants

TBS
Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Vitamin A deficiency (VAD) is still a serious public health problem in most developing countries. Several strategies are used to prevent and address the consequences of this deficiency and to reduce its prevalence, particularly in Africa. In Senegal, the prevalence of VAD, although low among women of reproductive age, is quite worrying among children under 5 years old. In 2009, the fortification of refined oil with vitamin A was made mandatory in addition to the strategies already in place. The study of the impact of these strategies on the vitamin A status of women and children, showed relatively stable prevalences between 2010 and 2018. However, this study used plasma retinol concentration as an indicator. It is known that evaluation of vitamin A status is relatively insensitive when based on changes in plasma retinol concentrations, which are homeostatically controlled and negatively affected by subclinical infections. Incremental studies in the Dakar region using the modified relative dose response (MRDR) test in children under 2 years of age have indicated adequate vitamin A stores and a low prevalence of vitamin A deficiency in these children. The various strategies to prevent and control vitamin A deficiency have reportedly improved and even increased vitamin A stores in women and children, particularly in the Dakar region. Indeed, the latter benefit from substantial intakes of preformed retinol through the fortification program, and the majority of children under 2 years of age are breastfed. The aim of this study is to use a more sensitive method than plasma retinol, the retinol isotope dilution (RID) test, to assess the actual status of subjects following these different strategies and to better orient the policies implemented in Senegal.

NCT ID: NCT05620199 Not yet recruiting - Surgery Clinical Trials

Upfront Resection of Locally Advanced NSCLC Followed by Chemoradiotherapy

UPLAN-I
Start date: April 1, 2023
Phase: N/A
Study type: Interventional

For patients with irresectable locally advanced non-small cell lung cancer (NSCLC) (e.g. multilevel or bulky N2 disease or presence of N3 lymph node metastases), current guidelines recommend treatment with chemoradiotherapy (CRT) followed by immune checkpoint inhibition (ICI, durvalumab). Chances of sterilization of a large (e.g. clinically staged T3 or T4 tumor) tumor volume by CRT alone are relatively small and these tumors are associated with a high local recurrence rate. Moreover, necrosis and cavitation of these tumors puts these patients at risk of fatal bleeding and might cause infectious complications, which lead to subsequent impaired quality of life (QoL) and to interruption of, or the need for postponing, (systemic) treatment. Upfront resection of the tumor in the lung, followed by postoperative CRT in patients who have a (potentially) resectable tumor could be a strategy to prevent complications of CRT in large volume and/or cavitating tumors with extensive mediastinal disease.

NCT ID: NCT05627765 Not yet recruiting - Smoking Cessation Clinical Trials

An Integrated Smoking Cessation and Alcohol Intervention for Young People

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The study will be a three-arm randomized controlled trial in a convenience sample of 150 smokers aged 18-25 years with a drinking habit who will be recruited from smoking hotspots in Mong Kok. Participants will be randomized into a standard treatment (ST), II, or control arm. Participants in the ST arm will receive a brief smoking cessation intervention based on the Asking about tobacco use, Advising smokers to quit, Assessing their willingness to quit, Assisting in quitting, and Arranging for follow-up and Relevance, Risks, Rewards, Roadblocks and Repetition models. Participants in the II arm will receive brief advice on alcohol use based on the FRAMES model in addition to the brief smoking cessation intervention. Booster interventions will be provided to both ST and II arms at 1-week, 1-month, 3-month, and 6-month follow-up. Participants in the control arm will receive leaflets on smoking cessation and alcohol abstinence. Data collection will be done at baseline and at 1-week, 1-month, 3-month, and 6-month follow-ups. Self-reported quitters at 6-month follow-up will be invited for biochemical validation.

NCT ID: NCT05630898 Not yet recruiting - Clinical trials for Congenital Cytomegalovirus

Congenital Cytomegalovirus: Prevalence in Buenos Aires City (cCMV Prevalence)

cCMV
Start date: April 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to recognise the prevalnce of congenital cytomegalovirus (cCMV) and to follow up positive babies until 12 months The main questions it aims to answer are: pevalence of cCMV, cCMV clinicals outcomes during the first year of life. Participants will be screened with a salive swab for CMV DNA. Babies with positive results will be follow up for one year.

NCT ID: NCT05649293 Not yet recruiting - Clinical trials for Vitamin b6 Level & Depression

Assesment of Vitamin B6 Level in Patients With Major Depressive Disorder

Start date: April 1, 2023
Phase:
Study type: Observational

Estimation of vitamin B 6 levels in diagnosed major depressive disorder patients and their relation to the severity of the disease

NCT ID: NCT05656300 Not yet recruiting - Glioblastoma Clinical Trials

Glioblastoma Imaging Using a Strong Iron-like Bloodpool Contrast Medium?

Start date: April 1, 2023
Phase:
Study type: Observational [Patient Registry]

Rationale: Visualization of tumor spread is of crucial importance when treating patients suffering from glioblastoma (GBM) as the success of tumor resection depends strongly on the extent of tumor infiltration. Current MRI protocols, however, cannot visualize the extent the tumor infiltration. The use of non-toxic, non-dangerous ultrasmall superparamagnetic biodegradable iron oxide (USPIO) particles as a very strong blood pool contrast agent could help visualizing this invisible infiltration Objective: To what extent, do GBMs infiltrate healthy brain tissue and can we use ultrasmall superparamagnetic iron oxide particles to visualize co-opting infiltrating tumor cells in an attempt to predict regions of tumor recurrence? Study design: This study concerns a single arm prospective observational study. Study population: Patients diagnosed with suspected glioblastoma. Intervention (if applicable): USPIO neuroimaging Main study parameters/endpoints: The main parameter of this study concerns the feasibility of using of USPIO particles in healthy controls (n=6) and glioblastoma patients (n=15). Nature and extent of the burden and risks associated with participation, benefit and group relatedness: During this study patients will be intravenously injected with low doses of USPIOs. Risks involved with this procedure include: bruising of the skin after venapunction and allergic reaction to USPIO particles. The application of USPIO neuroimaging can improve diagnosis of patients with suspected glioblastoma, provide more information on the pathophysiology of growth of glioblastoma lesiosn, the role of neuro-inflammation in these lesions and maybe predict regions of tumor recurrence after treatment.